Q: What Big Pharma drug that was once rejected by the FDA in a laughably bad application has a new lease on life in an altogether different disease area where it has seen some success in mid-stage trials?
A: ABT’s Atrasentan (f/k/a Xinlay).
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”